microRNA-125b 对系统性硬化症成纤维细胞凋亡与增殖的调控
该研究分析 miR-125b 在系统性硬化症(SSc)中的表达、调控及作用。SSc 皮肤活检和真皮成纤维细胞中 miR-125b 表达显著下调,其下调可增加凋亡、减少增殖及 α-SMA 表达,提示代偿性抗纤维化机制可能成为潜在治疗选择。
要点
- SSc 皮肤和真皮成纤维细胞中 miR-125b 表达显著下调。
- miR-125b 下调增加成纤维细胞凋亡并减少增殖及 α-SMA 表达。
- miR-125b 的代偿性抗纤维化机制可能为潜在治疗选项。
核心结论
- miR-125b 在 SSc 皮肤和原代真皮成纤维细胞中下调。
- miR-125b 下调增加成纤维细胞凋亡并减少增殖及 α-SMA 表达,提示其代偿性抗纤维化机制可能为潜在新治疗选择。
研究设计与样本
- 研究比较健康对照与 SSc 患者皮肤活检标本及真皮成纤维细胞中 miR-125b 表达,每组 n=10 样本。
- 通过 miR-125b 敲低后 RNA 测序及 qPCR、Western blotting 验证下游效应,并用 Caspase-Glo 3/7 等评估纤维化、凋亡和增殖。
主要发现
- SSc 皮肤活检标本中 miR-125b 表达较健康对照显著下调 53%(中位倍数变化 0.47,四分位距 0.35-0.69;P < 0.001)。
- SSc 真皮成纤维细胞中 miR-125b 表达较健康对照显著下调 47%(中位倍数变化 0.53,四分位距 0.36-0.58;P < 0.001)。
- 组蛋白去乙酰化酶抑制剂曲古抑菌素 A 和 tubastatin A 处理显著降低真皮成纤维细胞中 miR-125b 表达。
- miR-125b 敲低显著减少细胞增殖及 α-SMA 的 mRNA 和蛋白表达。
- RNA 测序识别 BAK1、BMF 和 BBC3 为 miR-125b 潜在靶点,qPCR 证实敲低 miR-125b 上调这些基因(P < 0.01;n=12),BAK1 蛋白水平诱导最强(P < 0.01;n=10)。
关键数值与推荐
- miR-125b 敲低增加凋亡,过表达减少凋亡。
临床怎么用
- SSc 中 miR-125b 下调可能通过增加成纤维细胞凋亡和减少增殖及 α-SMA 表达发挥抗纤维化作用,提示其作为潜在治疗靶点的可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the expression, regulation, and role of microRNA-125b (miR-125b) in systemic sclerosis (SSc). METHODS: MiR-125b expression was assessed by quantitative polymerase chain reaction (qPCR) of RNA from dermal fibroblasts and whole skin biopsy specimens from healthy controls and SSc patients. To identify downstream effectors, RNA from healthy control fibroblasts was sequenced after miR-125b knockdown and further validated using qPCR and Western blotting. Fibrosis, apoptosis, and proliferation were assessed by Caspase-Glo 3/7 assay, Western blotting, immunofluorescence staining for cleaved caspase 3, and annexin V real-time assay in dermal fibroblasts. RESULTS: Expression of miR-125b was significantly down-regulated in SSc skin biopsy specimens by 53% (median fold change 0.47 [interquartile range 0.35-0.69]; P < 0.001) and in SSc dermal fibroblasts by 47% (median fold change 0.53 [interquartile range 0.36-0.58]; P < 0.001) compared to healthy control skin biopsy specimens and fibroblasts, respectively (n = 10 samples per group). Treatment with the histone deacetylase inhibitors trichostatin A and tubastatin A significantly decreased the expression of miR-125b in dermal fibroblasts. MiR-125b knockdown significantly reduced cell proliferation and α-smooth muscle actin (α-SMA) expression at the messenger RNA (mRNA) and protein levels. RNA-Seq identified BAK1, BMF, and BBC3 as potential targets of miR-125b. Quantitative PCR confirmed that knockdown of miR-125b up-regulated these genes (P < 0.01; n = 12). Bcl-2 homologous antagonist killer 1 showed the strongest induction confirmed at the protein level (P < 0.01; n = 10). Consequently, miR-125b knockdown increased apoptosis compared to scrambled control. Accordingly, miR-125b overexpression decreased apoptosis. CONCLUSION: Our findings indicate that miR-125b is down-regulated in SSc skin and primary dermal fibroblasts. MiR-125b down-regulation increases apoptosis and decreases proliferation and α-SMA expression in dermal fibroblasts, indicating that its compensatory, antifibrotic mechanism may be a potential novel therapeutic option.
引用
- Kozlova A, Pachera E, Maurer B, et al. Regulation of Fibroblast Apoptosis and Proliferation by MicroRNA-125b in Systemic Sclerosis. Arthritis Rheumatol. 2019. PMID: 31309742. doi:10.1002/art.41041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。